2026年1月11日，第九届BFC医疗健康国际商务合作投资研讨会在旧金山瑞吉酒店圆满收官。逾1000位来自北美、欧洲与亚洲的产业领袖、投资人与创业者再度聚首，围绕“资本新流向”和“BD新浪潮”等主题，展开四场圆桌对话与26场企业路演，全面回顾并展望新一年全球医疗健康行业的机遇与挑战。

BFC Group创始人兼董事总经理David Chen以“Global Healthcare Capital & BD Outlook”为题作开场报告，他分享了过去一年全球医疗健康资本市场的新变化，为与会者带来深入浅出的行业洞察。

David Chen, Founder & Managing Director, BFC Group

大会的第一场圆桌讨论以“Capital Shifts – The Evolving Global Biotech Investment Landscape”为主题，主持人和嘉宾回顾了过去一年生物科技市场回暖、亚洲BD交易激增和早期生态重塑等关键趋势，还探讨了如何在新一轮估值重置中捕捉机会，并分析如何在短期收益与长期创新之间取得平衡。

从左往右：Patrick Loofbourrow, Partner, Cooley; Ran Geng, Principal, OrbiMed; Brian Chow, Managing Director, Deerfield Management; Kevin Chen, Founding Partner & CEO, BioTrack Capital; Ricky Sun, Partner, Bain Capital; Amit Kakar, Managing Partner and Head of Asia, Novo Holdings

大会的第二场圆桌讨论以“From Asia to the World – Redefining Global Pharma Collaboration”为主题，主持人和嘉宾围绕中国创新在全球管线中的角色升级展开对话，回顾从传统授权到共担风险、共享收益的协作新范式。他们交流了中国伙伴在执行速度与数据质量上的优势，并探讨如何在更紧密的合作中保持平台价值的独立与可持续，为跨境合作提供多维度实践参考。

从左往右：Thijs Spoor, CEO, Perspective Therapeutics; Julie Rozenblyum, Senior Vice President, Business Development, Bristol Myers Squibb; Markus Werner, Head Search & Evaluation Oncology, Novartis; Johan Verbeeck, Vice President Business Development, Oncology, Johnson & Johnson Innovative Medicine; Michelle Li, Senior Vice President, Head of Business Development, Alnylam Pharmaceuticals; Wendy Liu, Vice President, Worldwide Business Development, Pfizer

大会的第三场圆桌讨论以“The Rise of Therapeutic Convergence – Addressing Unmet Needs with New Frontiers”为主题，主持人和嘉宾围绕肿瘤、免疫、代谢、CNS与眼科的学科边界日益模糊展开对话，并展望跨系统靶点与递送技术带来的下一波差异化机会，为听众描绘出跨领域治疗时代的BD导航图。

从左往右：Lila Hope, Partner, Cooley; Matthieu Merlin, Head of Business Development General Medicines GBU, Sanofi; Tomohiro Yamauchi, Head of Scouting & Transaction Oncology, Business Development, Astellas Pharma; Remko Bakker, Global Head of Eye Health and Research Beyond Borders, Boehringer Ingelheim; Enza Di Modugno, Vice President, Global Business Development Head CVRM, Immunology, Infectious Diseases – Roche; Albert Ren, Vice President, Head of Worldwide Business Development China, Pfizer

会议午餐开启轻松交流时段，参会者在餐叙间互换名片、相约后续洽谈。随后举行的公司路演共集结26家国内外医药与医疗企业，轮番展示最新管线与技术平台，吸引大批潜在合作方与投资人驻足聆听。

大会的第四场圆桌讨论以“Accessing Early Innovation – Shaping the Next Wave of Biotech”为主题，主持人和嘉宾探讨如何识别并评估早期公司与学术平台，如何在“单一资产授权”与“长期平台共建”之间抉择。他们还分享了跨区域、跨文化的合作心态与机制升级，为听众勾勒出一条“亚洲原创—全球加速”的务实路径。

从左往右：Roel van den Akker, Partner, Pharmaceutical & Life Science Deals Leader, PwC US; Neville Mehenti, Executive Director, Head of Oncology Corporate Development, Gilead Science; Eric Yeung, Vice President, Head of Oncology and Rare Diseases Global Business Development, Takeda; Regina Salvat, Principal, Forbion; Ryan Wang, Vice President, Head of Lilly China Innovation and Partnerships, Eli Lilly; Mads Frederik Rasmussen, Senior Vice President, R&D External Innovation, Novo Nordisk

1场宏观洞察、4场圆桌交锋、26场路演分享，共吸引逾1000位全球嘉宾齐聚旧金山。第九届BFC医疗健康国际商务合作投资研讨会在深入的思想碰撞与合作机遇的充分交流中圆满收官。BFC Group将持续搭建东西方生物医药创新与资本交汇的桥梁，2027年，我们再相聚！